Your browser doesn't support javascript.
loading
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Ludwig, Heinz; Terpos, Evangelos; van de Donk, Niels; Mateos, Maria-Victoria; Moreau, Philippe; Dimopoulos, Melitios-Athanasios; Delforge, Michel; Rodriguez-Otero, Paula; San-Miguel, Jesús; Yong, Kwee; Gay, Francesca; Einsele, Hermann; Mina, Roberto; Caers, Jo; Driessen, Christoph; Musto, Pellegrino; Zweegman, Sonja; Engelhardt, Monika; Cook, Gordon; Weisel, Katja; Broijl, Annemiek; Beksac, Meral; Bila, Jelena; Schjesvold, Fredrik; Cavo, Michele; Hajek, Roman; Touzeau, Cyrille; Boccadoro, Mario; Sonneveld, Pieter.
Afiliación
  • Ludwig H; Department of Medicine, Clinic Ottakring, Wilhelminen Cancer Research Institute, Vienna, Austria. Electronic address: heinz.ludwig@extern.gesundheitsverbund.at.
  • Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • van de Donk N; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands.
  • Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Salamanca, Spain.
  • Moreau P; Department of Hematology, University Hospital of Nantes, Nantes, France.
  • Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Delforge M; Division of Hematology, University of Leuven, Leuven, Belgium.
  • Rodriguez-Otero P; Cancer Center Clinica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Medica Aplicada, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Centro de investigación biomédica en red de Oncologia, Pamplona, Spain.
  • San-Miguel J; Cancer Center Clinica Universidad de Navarra, Pamplona, Spain; Centro de Investigación Medica Aplicada, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Centro de investigación biomédica en red de Oncologia, Pamplona, Spain.
  • Yong K; University College London Cancer Institute, London, UK.
  • Gay F; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
  • Einsele H; Department of Internal Medicine, University Hospital Würzburg, Germany.
  • Mina R; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
  • Caers J; Department of Hematology, CHU de Liège, Liège, Belgium.
  • Driessen C; Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland.
  • Musto P; Department of Precision and Regenerative Medicine and Ionian Area, Aldo Moro University School of Medicine, Bari, Italy; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
  • Zweegman S; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, Netherlands.
  • Engelhardt M; Department of Hematology, Oncology and Stem Cell Transplantation, Clinical Cancer Research Group, Universitätsklinikum Freiburg, Freiburg, Germany.
  • Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, University of Leeds, Leeds, UK.
  • Weisel K; Universitätsklinikum Hamburg-Eppendorf, Medizinische Klinik und Poliklinik, Hamburg, Germany.
  • Broijl A; Erasmus MC Cancer Institute & Erasmus University of Rotterdam, Rotterdam, Netherlands.
  • Beksac M; Department of Hematology, Ankara University, Ankara, Türkiye.
  • Bila J; Clinic of Hematology, University Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Schjesvold F; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, SeràgnoliIstituto di Ematologia, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Hajek R; Department of Hemato-Oncology, University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Touzeau C; Department of Hematology, University Hospital of Nantes, Nantes, France.
  • Boccadoro M; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
  • Sonneveld P; Erasmus MC Cancer Institute & Erasmus University of Rotterdam, Rotterdam, Netherlands.
Lancet Oncol ; 24(6): e255-e269, 2023 06.
Article en En | MEDLINE | ID: mdl-37269857
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Anticuerpos Biespecíficos / Mieloma Múltiple Tipo de estudio: Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Asunto principal: Anticuerpos Biespecíficos / Mieloma Múltiple Tipo de estudio: Etiology_studies / Guideline Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article